Eli Lilly announced that its experimental obesity drug, retatrutide, demonstrated broad benefits, including curbing sleep apnea. The company is also making strategic moves in the vaccine market and is projected for significant growth.

Eli Lilly (LLY) has reported positive Phase 3 clinical trial results for its investigational obesity treatment, Retatrutide, marking a significant development in the pharmaceutical company's pipeline.

Selskabet Eli Lilly vil have fat i svært overvægtige patienter med sit middel retatrutide, skriver Reuters.

A concerning new trend is emerging among teenagers involving the cheap acquisition and use of retatrutide, a triple-agonist weight-loss drug known as r3ta, prompting alarm from medical professionals.

Lilly is betting big on retatrutide as the next pillar of its obesity portfolio after its weight loss injection Zepbound and its upcoming pill, orforglipron.

CNBC reports that Eli Lilly has announced robust Phase 3 trial results for its drug Retatrutide, indicating promising efficacy.

Eli Lilly announced clinical trial results for retatrutide, its next gen obesity drug. The drug helped study participants lose 70 lbs over 80 weeks, making it more powerful than Zepbound and Wegovy.

A new weight loss drug, Retatrutide, has delivered stunning results in trials, offering a potential breakthrough for individuals seeking effective weight management solutions.

Experts are raising alarms as retatrutide, a peptide injection still undergoing clinical trials as an obesity drug, has already appeared on the black market, preying on patient demand.

Looksmaxxing influencer Braden Peters revealed the daily drug cocktail he uses to pursue his ideal physique, including testosterone, retatrutide, and other supplements.

Eli Lilly has reported positive Phase 3 clinical trial results for its investigational obesity treatment, Retatrutide, with its latest GLP-1 drug showing significant promise as a powerful weapon in the fight against obesity.

A new injectable drug for obesity, Retatrutide, is being hailed by experts as a powerful new tool in the fight against excess weight. It promises weight loss results comparable to physical exercise with just a single injection.

A new triple-agonist GLP-1 therapy called retatrutide is being explored for its potential to reduce side effects and preserve muscle mass during weight loss, with discussions involving figures like Gwyneth Paltrow and neuroscientist Andrew Huberman.

Users of the unapproved weight-loss drug retatrutide are reporting a side effect described as 'emotional flattening,' prompting experts to investigate the complex picture behind these claims.

A new drug, Retatrutide, is entering the weight-loss market, targeting metabolism, appetite, and energy expenditure, with clinical trials concluding in March and promising a 25% reduction in body weight.